Malin Corp: Poseida positive data for P-BCMA-101

Malin Corporation plc

("Malin" or "the Company")

Poseida Therapeutics announces positive clinical data on its lead CAR-T therapeutic candidate, P-BCMA-101, at the 2018 ASH Annual Meeting

- Malin owns approximately one third of Poseida, a Malin Priority Portfolio Asset -

Dublin-Ireland, 4 December 2018: Malin Corporation plc. (ISE:MLC, "Malin"), a company investing in highly innovative life sciences companies, is pleased to note the positive data presented at the 2018 American Society of Hematology (ASH) Annual Meeting by its investee company, Poseida Therapeutics Inc. ("Poseida"), on the ongoing Phase 1 clinical trial of its lead autologous P-BCMA-101, a CAR-T therapeutic candidate for patients with relapsed/refractory multiple myeloma.

As of the data cutoff date on 29 November 2018, Poseida, one of Malin's four Priority Assets, had treated 23 patients in its ongoing Phase 1 clinical trial. P-BCMA-101 showed a 100% objective response rate in patients receiving the planned Phase 2 dose, and rapid and deep responses were observed in all patients, with no cytokine release syndrome (CRS) or neurotoxicity observed at the highest dosing levels.

Poseida intends to pursue a registrational clinical trial for P-BCMA-101, expected to be the basis for initial regulatory approval, in the first half of 2019, with the objective of filing a biologics licence application by the end of 2020.

Malin believes these Phase 1 data indicate that Poseida's CAR-T product candidate, which is comprised of a high percentage of stem cell memory T cells, is differentiated and has significant potential to result in a gradual peak expansion leading to improved response rates with a favourable safety profile compared to published results from clinical trials of other CAR-T therapies at similar doses.

Malin owns an approximate 33% stake in Poseida and carried its investment in Poseida at €99.4 million at 30 June 2018 in its portfolio fair value estimate under International Private Equity Valuation guidelines.

A copy of Poseida's press release is available to view here:

https://poseida.com/4200-2/

Malin

Jessica Bergin, Director of Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Consilium Strategic Communications (Financial PR)

Mary-Jane Elliott / Jonathan Birt

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Ireland PR)

Eavan Gannon

Tel: +353 87 236 5973

Davy Corporate Finance (ESM Adviser)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

About Malin Corporation plc

Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin. For more information visit www.malinplc.com